PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0970
Abstract: CDKN2A/B homozygous deletion (HoD) in IDH-mutant astrocytomas is associated with poor prognosis and now defines WHO grade 4 status, regardless of histology. We hypothesized that CDKN2A loss resulting from CDKN2A/B HoD drives biological changes independent… read more here.
Keywords: astrocytomas; cell; idh; cdkn2a loss ... See more keywords
Clinical and Genomic Analysis of Patients With Short Survival After Surgery for Esophageal Squamous Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Digestive diseases"
DOI: 10.1159/000527983
Abstract: OBJECTIVE To investigate the prognosis of Chinese patients with ESCC after surgery and its correlation with genomic alterations (GAs) to identify potential prognostic markers. METHODS The clinical information, pathological specimens of 50 patients with stage… read more here.
Keywords: cell carcinoma; escc; squamous cell; group ... See more keywords
Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.308
Abstract: 308 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with EC with… read more here.
Keywords: disease; loss; rate; mut ... See more keywords